Patents by Inventor Yufeng XIAO

Yufeng XIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230330237
    Abstract: Modulators of Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) are described as well as their use as therapeutic agents for disease, disorders, or symptoms thereof, including those where modulation of NR4A1 is implicated. Such disease and disorders include cancer.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 19, 2023
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Weizhou Zhang, Guangrong Zheng, Daohong Zhou, Yufeng Xiao, Lei Wang
  • Publication number: 20230181746
    Abstract: In one aspect, the disclosure relates to benzoylhydrazide-derived PROTACs that are highly effective at degrading HDAC3 and that are also capable of targeting, to a lesser extent, other HDAC isoforms, methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers including hematologic cancers, breast cancer, other malignancies, and other serious diseases involving aberrant HDAC activity using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Application
    Filed: May 17, 2021
    Publication date: June 15, 2023
    Inventors: Daiqing LIAO, Yufeng XIAO, Xuan ZHANG, Guangrong ZHENG
  • Patent number: 11098071
    Abstract: The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 24, 2021
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Xin Xie, Linhai Chen, Qing Zhang, Yufeng Xiao, Hui Yang
  • Publication number: 20200010492
    Abstract: The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.
    Type: Application
    Filed: February 28, 2016
    Publication date: January 9, 2020
    Inventors: Fajun NAN, Xin XIE, Linhai CHEN, Qing ZHANG, Yufeng XIAO, Hui YANG